Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Employees - 95000,
CEO - Mr. Geoffrey Straub Martha,
Sector - Healthcare,
Country - IE,
Market Cap - 105.25B
Altman ZScore(max is 10): 2.73, Piotroski Score(max is 10): 6, Working Capital: $10243000000, Total Assets: $90042000000, Retained Earnings: $30919000000, EBIT: 6549000000, Total Liabilities: $41326000000, Revenue: $32996000000
AryaFin Target Price - $100.75 - Current Price $81.03 - Analyst Target Price $94.54
Ticker | MDT |
Index | S&P 500 |
Curent Price | 81.03 |
Change | 1.30% |
Market Cap | 105.25B |
Average Volume | 5.83M |
Income | 4.29B |
Sales | 33.00B |
Book Value/Share | 37.81 |
Cash/Share | 6.15 |
Dividend Est | 2.71 (3.35%) |
Dividend TTM | 2.78 (3.43%) |
Dividend Ex-Date | Dec 27, 2024 |
Employees | 95000 |
Moving Avg 20days | -3.28% |
Moving Avg 50days | -6.82% |
Moving Avg 200days | -3.95% |
Shares Outstanding | 1.28B |
Earnings Date | Nov 19 BMO |
Inst. Ownership | 84.63% |
Price/Earnings | 24.73 |
Forwad P/E | 13.87 |
PE Growth | 4.30 |
Price/Sales | 3.19 |
Price/Book | 2.14 |
Price/Cash | 13.17 |
Price/FCF | 19.14 |
Quick Ratio | 1.39 |
Current Ratio | 1.84 |
Debt/Equity | 0.58 |
Return on Assets | 4.76% |
Return on Equity | 8.58% |
Return on Investment | 5.87% |
Gross Margin | 60.08% |
Ops Margin | 17.93% |
Profit Margin | 13.00% |
RSI | 30.83 |
BETA(β) | 0.84 |
From 52week Low | 6.67% |
From 52week High | -12.57% |
EPS | 3.28 |
EPS next Year | 5.84 |
EPS next Qtr | 1.36 |
EPS this Year | 4.81% |
EPS next 5 Year | 5.75% |
EPS past 5 Year | -4.12% |
Sales past 5 Year | 1.24% |
EPS Y/Y | 6.56% |
Sales Y/Y | 3.25% |
EPS Q/Q | 44.60% |
Sales Q/Q | 5.25% |
Sales Surprise | 1.55% |
EPS Surprise | 0.83% |
ATR(14) | 1.33 |
Perf Week | -1.76% |
Perf Month | -3.66% |
Perf Quarter | -9.83% |
Perf Year | 0.52% |
Perf YTD | -1.64% |
Target Price | 94.54 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer